Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
08:10am, Wednesday, 24'th Aug 2022
The best-known growth ETF money manager is making moves. Let's check out her shopping list.
3 Growth Stocks That Could Soar 51% to 385%, According to Wall Street
06:03am, Monday, 22'nd Aug 2022
Expectations for these stocks are still sky high.
3 Growth Stocks That Could Soar 35% to 84%, According to Wall Street
06:08am, Saturday, 20'th Aug 2022
Analysts still have great expectations for these beaten-down stocks.
5 Top Stocks Cathie Wood Bought This Week
05:02pm, Friday, 05'th Aug 2022
Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
01:32pm, Wednesday, 03'rd Aug 2022
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Exact Sciences Stock Falls After Earnings. Here's What Wall Street Is Saying.
12:54pm, Wednesday, 03'rd Aug 2022
June quarter sales were $522 million, representing 26% growth if one backs out last year's sales bump from Covid-19 tests
Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2022 Results - Earnings Call Transcript
07:16pm, Tuesday, 02'nd Aug 2022
Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET Company Participants Megan Jones - Senior Director, Investor Relations Kevin Conroy - Chairman & Ch
Exact Sciences to participate in August investor conference
06:00am, Monday, 01'st Aug 2022
MADISON, Wis. , Aug. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
01:56pm, Monday, 25'th Jul 2022
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
6 Cathie Wood Stocks to Buy on the Dip
11:21am, Thursday, 14'th Jul 2022
As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. The post 6 Cathie Wood Stocks to Buy on the Dip appeared firs
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:15am, Thursday, 14'th Jul 2022
The best-known growth ETF money manager is making moves. Let's check out her shopping list.
2 Cancer-Focused Stocks That Could Soar, According to Wall Street
11:15am, Wednesday, 13'th Jul 2022
Let's look beyond short-term price targets analysts assign.
Exact Sciences schedules second quarter 2022 earnings call
06:00am, Friday, 08'th Jul 2022
MADISON, Wis. , July 8, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its sec
Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes
11:44am, Thursday, 30'th Jun 2022
Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.
Exact Sciences (EXAS) Surges 6.9%: Is This an Indication of Further Gains?
10:46am, Monday, 27'th Jun 2022
Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
